ライフサイエンスコーパス: epistaxis

1 ilate pretreatment (three haematuria and one epistaxis).

2 to the emergency department with intractable epistaxis.

3 d reduced duration and number of episodes of epistaxis.

4 in children, as in adults, were headache and epistaxis.

5 comes included the frequency and duration of epistaxis.

6 a finding consistent with moderate-to-severe epistaxis.

7 nts), gastrointestinal bleeding (1 patient), epistaxis (1 patient), and antibiotic-responsive febrile

8 nt-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]

9 davunetide group than in the placebo group (epistaxis 18 [12%] of 156 vs 13 [8%] of 156, rhinorrhoea

10 t (AE) (most commonly fatigue, headache, and epistaxis); 19% (n = 12) reported >/=1 serious AE; 10 (1

11 38%]), anemia (5 patients [9%] vs 27 [44%]), epistaxis (2 patients [4%] vs 34 [56%]), and hypertensio

12 33 (25%) patients (70% gastrointestinal, 21% epistaxis, 3% genitourinary, and 6% intracranial).

13 ncluded alopecia (38 [38%] of 101 patients), epistaxis (30 [30%]), nausea (27 [27%]), conjunctivitis

14 common adverse events with sotatercept were epistaxis (31.9%) and telangiectasia (26.2%).

15 intestinal (45% of events), wound (12%), and epistaxis (4%).

16 The main adverse effects were epistaxis, affecting 12 of 124 participants (9.7%) in th

17 ctatic bleeding, primarily causing recurrent epistaxis and chronic gastrointestinal bleeding, is the

18 the use of sclerotherapy for HHT-associated epistaxis and cutaneous telangiectasias, participated in

19 These three individuals had epistaxis and dermal lesions that were described as tela

20 Management goals encompass control of epistaxis and intestinal bleeding from telangiectases, s

21 Her mother was reported to have frequent epistaxis and similar skin lesions.

22 common adverse events with sotatercept were epistaxis and telangiectasia.

23 of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycaemia).

24 sorders presented with abdominal distension, epistaxis, and anemia (hemoglobin 8.2 g/dL).

25 Minor bleeding of the skin bruises, epistaxis, and gum bleeding were most frequent.

26 sening of nasal polyps and asthma, headache, epistaxis, and injection-site erythema) were more freque

27 ngiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of life

28 d patients; postprocedural bleeding (in 3%); epistaxis associated with the use of fish-oil supplement

29 gh, sore throat, nausea, vomiting, diarrhea, epistaxis, bleeding gums, menorrhagia, and melena in hum

30 The frequency of epistaxis decreased from 30 to 15 episodes per month.

31 with sotatercept than with placebo included epistaxis, dizziness, telangiectasia, increased hemoglob

32 Mean monthly epistaxis duration for 3 consecutive months immediately

33 pared with a placebo, did not reduce monthly epistaxis duration in the 3 consecutive months immediate

34 Mean monthly epistaxis duration measured at 3 months was not signific

35 The mean monthly epistaxis duration was 259.2 minutes (95% CI, 82.1-436.3

36 0+/-36.0% with placebo; the mean decrease in epistaxis duration was 29.9+/-53.2%, 41.4+/-41.0%, and 2

37 was significantly different from placebo for epistaxis duration.

38 condary outcomes included median duration of epistaxis during weeks 5 through 12, Epistaxis Severity

39 an presented with left nasal obstruction and epistaxis for 2 years and was diagnosed with nasopharyng

40 atient department with recurrent episodes of epistaxis for the past 8 years and altered behavior for

41 Drug therapy did not significantly reduce epistaxis frequency (P = .97).

42 b treatment was associated with decreases in epistaxis frequency and duration.

43 The primary outcome was median weekly epistaxis frequency during weeks 5 through 12.

44 ine to week 12, the mean (+/-SD) decrease in epistaxis frequency was 26.5+/-26.5% with 30-mg engasert

45 vs estriol vs tranexamic acid vs placebo and epistaxis frequency.

46 ectasia overlap syndrome) that can result in epistaxis, gastrointestinal bleeding from mucocutaneous

47 's thrombasthenia usually includes bruising, epistaxis, gingival hemorrhage, and menorrhagia.

48 3 months prior to inclusion corroborated by epistaxis grids completed during the same preinclusion p

49 ia based on (1) nearly a lifelong history of epistaxis, gum bleeding, petechiae, and purpura; (2) sev

50 elial growth factor monoclonal antibody) for epistaxis has been shown.

51 red colony and experienced clinical signs of epistaxis, hyphema, intramuscular hematoma, and prolonge

52 ile neutropenia, catheter-related infection, epistaxis, hypotension, nausea, and fever.

53 d embolization to management of postraumatic epistaxis in 1970.

54 ntial role for Bartonella spp. as a cause of epistaxis in dogs and potentially in other animals, incl

55 lla species was implicated in three cases of epistaxis in dogs, based upon isolation, serology, or PC

56 The North American Study of Epistaxis in HHT was a double-blind, placebo-controlled

57 higher incidence of CRNM bleeding (primarily epistaxis in younger children) occurred in participants

58 vents occurred following randomisation: one (epistaxis) in the booster group and three (gastrointesti

59 adiation recall (n = 1), grade 3 hemorrhage (epistaxis) in the presence of grade 4 thrombocytopenia (

60 Children usually experience isolated epistaxis; in rare cases, childhood complications occur

61 omen with a median of 7.0 weekly episodes of epistaxis [interquartile range {IQR}, 3.0-14.0]), 106 pa

62 Epistaxis is a major factor negatively affecting quality

63 Epistaxis is the most frequent and disabling manifestati

64 Optimal treatment for HHT-related epistaxis is uncertain.

65 rgent adverse event during period 1, notably epistaxis, madarosis and skin abscesses.

66 Medication logs, pain scores, and epistaxis measures were collected until postoperative da

67 dominant vascular disorder characterized by epistaxis, mucocutaneous telangiectases, and arterioveno

68 ross treatment groups were petechiae (n=20), epistaxis (n=16), and headache (n=14).

69 on deficiency and anaemia owing to recurrent epistaxis (nosebleeds) or bleeding from gastrointestinal

70 g loss, vertigo, rhinitis or rhinosinusitis, epistaxis, obstructive sleep apnea, sialorrhea, voice ch

71 nce of CRNM bleeding, primarily grade 1 or 2 epistaxis, occurred in the apixaban group (11 [4%] of 25

72 ne in the 5 g plus 2.5 g idarucizumab group (epistaxis); one receiving placebo (infusion site haemato

73 ed in treatment of spontaneous and traumatic epistaxis, palliative tumors and vascular defects, as we

74 change from baseline through week 24 in the Epistaxis Severity Score (a validated bleeding score in

75 All groups had a significant improvement in Epistaxis Severity Score at weeks 12 and 24.

76 ad experienced HHT-related epistaxis with an Epistaxis Severity Score of at least 3.0.

77 ebo group in the change from baseline in the Epistaxis Severity Score was -0.94 points (95% confidenc

78 The baseline mean (+/-SD) Epistaxis Severity Score was 5.0+/-1.5, a finding consis

79 tion of epistaxis during weeks 5 through 12, Epistaxis Severity Score, level of hemoglobin, level of

80 ignificant, clinically relevant reduction in epistaxis severity.

81 The primary clinical manifestation is epistaxis that results in iron-deficiency anemia and red

82 He had a prior history of epistaxis typically lasting 5-10 minutes and consisting

83 There were five cases of mild epistaxis upon bridle insertion and four cases of superf

84 Epistaxis was scanty in amount, intermittent, spontaneou

85 The epistaxis was treated with nasal packing, which prevente

86 Hypertension, proteinuria, and epistaxis were other potential safety concerns.

87 Mean duration of epistaxis, which was 221 minutes per month (range, 0-947

88 eria for HHT and had experienced HHT-related epistaxis with an Epistaxis Severity Score of at least 3